Reversed a judgment that a patent for a pharmaceutical product was invalid on the ground of obviousness. The Federal Circuit concluded that obviousness was not proved by clear and convincing evidence.
Thank you for subscribing!
FindLaw Newsletters
The email address cannot be subscribed. Please try again.
Learn more about FindLaw’s newsletters, including our terms of use and privacy policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.